GLUE vs. RCUS, SYRE, ELVN, PHVS, AVDL, NAGE, NTLA, ARDX, CRMD, and CMRX
Should you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), Enliven Therapeutics (ELVN), Pharvaris (PHVS), Avadel Pharmaceuticals (AVDL), Niagen Bioscience (NAGE), Intellia Therapeutics (NTLA), Ardelyx (ARDX), CorMedix (CRMD), and Chimerix (CMRX). These companies are all part of the "pharmaceutical products" industry.
Monte Rosa Therapeutics vs.
Arcus Biosciences (NYSE:RCUS) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
Arcus Biosciences received 184 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 65.57% of users gave Arcus Biosciences an outperform vote while only 48.48% of users gave Monte Rosa Therapeutics an outperform vote.
Arcus Biosciences has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.
Monte Rosa Therapeutics has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Monte Rosa Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Arcus Biosciences' return on equity of -45.59% beat Monte Rosa Therapeutics' return on equity.
Arcus Biosciences currently has a consensus price target of $25.67, suggesting a potential upside of 197.24%. Monte Rosa Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 286.53%. Given Monte Rosa Therapeutics' higher possible upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than Arcus Biosciences.
In the previous week, Arcus Biosciences had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 7 mentions for Arcus Biosciences and 4 mentions for Monte Rosa Therapeutics. Arcus Biosciences' average media sentiment score of 1.49 beat Monte Rosa Therapeutics' score of 1.46 indicating that Arcus Biosciences is being referred to more favorably in the media.
92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by company insiders. Comparatively, 6.9% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Arcus Biosciences beats Monte Rosa Therapeutics on 12 of the 19 factors compared between the two stocks.
Get Monte Rosa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monte Rosa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GLUE) was last updated on 5/22/2025 by MarketBeat.com Staff
